FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101059527> ?p ?o ?g. }

• W2101059527 endingPage "S50.e23" @default.
• W2101059527 startingPage "S50.e1" @default.
• W2101059527 abstract "HIV/AIDS is currently the leading cause of death in Africa and the fourth leading cause of death worldwide. This systematic review of the literature was conducted to evaluate the evidence for treatment of the most common oral lesions associated with HIV: oral candidiasis with or without oropharyngeal involvement (OPC), oral hairy leukoplakia (OHL), recurrent aphthous-like ulcerations (RAU), oral Kaposi’s sarcoma (OKS), orolabial herpes simplex infection (HSV), oral herpes zoster infection (VZV), intraoral or perioral warts (HPV), and HIV-associated periodontal diseases. Treatment of HIV-associated salivary gland disease is addressed in a different section of this World Workshop. We found the largest body of evidence for treatment of OPC in HIV patients. Future trials will be needed to test drugs currently in development for treatment of Candida strains that are resistant to existing therapies. There were no double blind, placebo-controlled randomized clinical trials (RCT) for topical treatment of OHL, and only one RCT for systemic treatment of the lesion with desciclovir. Systemic thalidomide was the only drug tested in RCT for treatment or prevention of RAU. Only 1 double-blind RCT comparing vinblastine and sodium tetradecyl sulfate was identified for localized treatment of OKS. Three drugs (famciclovir, acyclovir, and valaciclovir) were shown to be effective in randomized, double-blind trials for treatment or suppression of mucocutaneous HSV lesions in HIV patients. In all 3 trials, the effects of these medications on orolabial HSV lesions were not reported separately. There were no double-blind, placebo-controlled RCT testing topical treatments for orolabial HSV lesions in HIV patients. No trials testing treatments of oral VZV were identified. There were no double-blind, placebo-controlled RCT for treatment of HIV-associated intraoral or perioral warts or periodontal diseases. In conclusion, there is a need for well-designed RCTs to assess the safety and efficacy of topical and systemic treatments of most oral mucosal and perioral lesions in HIV patients. There is also a need to develop newer drugs for treatment of resistant fungal and viral microorganisms. Finally, standardized outcome measures should be developed for future clinical trials to allow comparisons of studies using different populations. HIV/AIDS is currently the leading cause of death in Africa and the fourth leading cause of death worldwide. This systematic review of the literature was conducted to evaluate the evidence for treatment of the most common oral lesions associated with HIV: oral candidiasis with or without oropharyngeal involvement (OPC), oral hairy leukoplakia (OHL), recurrent aphthous-like ulcerations (RAU), oral Kaposi’s sarcoma (OKS), orolabial herpes simplex infection (HSV), oral herpes zoster infection (VZV), intraoral or perioral warts (HPV), and HIV-associated periodontal diseases. Treatment of HIV-associated salivary gland disease is addressed in a different section of this World Workshop. We found the largest body of evidence for treatment of OPC in HIV patients. Future trials will be needed to test drugs currently in development for treatment of Candida strains that are resistant to existing therapies. There were no double blind, placebo-controlled randomized clinical trials (RCT) for topical treatment of OHL, and only one RCT for systemic treatment of the lesion with desciclovir. Systemic thalidomide was the only drug tested in RCT for treatment or prevention of RAU. Only 1 double-blind RCT comparing vinblastine and sodium tetradecyl sulfate was identified for localized treatment of OKS. Three drugs (famciclovir, acyclovir, and valaciclovir) were shown to be effective in randomized, double-blind trials for treatment or suppression of mucocutaneous HSV lesions in HIV patients. In all 3 trials, the effects of these medications on orolabial HSV lesions were not reported separately. There were no double-blind, placebo-controlled RCT testing topical treatments for orolabial HSV lesions in HIV patients. No trials testing treatments of oral VZV were identified. There were no double-blind, placebo-controlled RCT for treatment of HIV-associated intraoral or perioral warts or periodontal diseases. In conclusion, there is a need for well-designed RCTs to assess the safety and efficacy of topical and systemic treatments of most oral mucosal and perioral lesions in HIV patients. There is also a need to develop newer drugs for treatment of resistant fungal and viral microorganisms. Finally, standardized outcome measures should be developed for future clinical trials to allow comparisons of studies using different populations." @default.
• W2101059527 created "2016-06-24" @default.
• W2101059527 creator A5008944286 @default.
• W2101059527 creator A5013466490 @default.
• W2101059527 creator A5039328990 @default.
• W2101059527 creator A5045588575 @default.
• W2101059527 creator A5054403402 @default.
• W2101059527 creator A5072215036 @default.
• W2101059527 date "2007-03-01" @default.
• W2101059527 modified "2023-10-12" @default.
• W2101059527 title "Management of oral lesions in HIV-positive patients" @default.
• W2101059527 cites W1487143634 @default.
• W2101059527 cites W1519450433 @default.
• W2101059527 cites W1526332344 @default.
• W2101059527 cites W1531346399 @default.
• W2101059527 cites W1533542302 @default.
• W2101059527 cites W1581407744 @default.
• W2101059527 cites W1847067998 @default.
• W2101059527 cites W1860882807 @default.
• W2101059527 cites W1928599069 @default.
• W2101059527 cites W1962046702 @default.
• W2101059527 cites W1963878522 @default.
• W2101059527 cites W1968115779 @default.
• W2101059527 cites W1968475599 @default.
• W2101059527 cites W1968561314 @default.
• W2101059527 cites W1970265451 @default.
• W2101059527 cites W1970558739 @default.
• W2101059527 cites W1971005199 @default.
• W2101059527 cites W1972178095 @default.
• W2101059527 cites W1974520996 @default.
• W2101059527 cites W1977447261 @default.
• W2101059527 cites W1979241418 @default.
• W2101059527 cites W1979329236 @default.
• W2101059527 cites W1981584719 @default.
• W2101059527 cites W1984513537 @default.
• W2101059527 cites W1986061600 @default.
• W2101059527 cites W1987846062 @default.
• W2101059527 cites W1989042627 @default.
• W2101059527 cites W1990114052 @default.
• W2101059527 cites W1990271774 @default.
• W2101059527 cites W1990865349 @default.
• W2101059527 cites W1993529053 @default.
• W2101059527 cites W1994614811 @default.
• W2101059527 cites W1994785091 @default.
• W2101059527 cites W1995216323 @default.
• W2101059527 cites W1997463913 @default.
• W2101059527 cites W2002508906 @default.
• W2101059527 cites W2002986598 @default.
• W2101059527 cites W2003965546 @default.
• W2101059527 cites W2005626046 @default.
• W2101059527 cites W2006659256 @default.
• W2101059527 cites W2008293714 @default.
• W2101059527 cites W2008835015 @default.
• W2101059527 cites W2009276643 @default.
• W2101059527 cites W2012352057 @default.
• W2101059527 cites W2014387200 @default.
• W2101059527 cites W2015336562 @default.
• W2101059527 cites W2015819915 @default.
• W2101059527 cites W2019534962 @default.
• W2101059527 cites W2020275501 @default.
• W2101059527 cites W2020960129 @default.
• W2101059527 cites W2021264348 @default.
• W2101059527 cites W2021666478 @default.
• W2101059527 cites W2022624614 @default.
• W2101059527 cites W2024310762 @default.
• W2101059527 cites W2026786199 @default.
• W2101059527 cites W2027527630 @default.
• W2101059527 cites W2028528167 @default.
• W2101059527 cites W2029180303 @default.
• W2101059527 cites W2031710879 @default.
• W2101059527 cites W2031740347 @default.
• W2101059527 cites W2034182840 @default.
• W2101059527 cites W2035476145 @default.
• W2101059527 cites W2036987350 @default.
• W2101059527 cites W2037682425 @default.
• W2101059527 cites W2037773098 @default.
• W2101059527 cites W2038198483 @default.
• W2101059527 cites W2040687315 @default.
• W2101059527 cites W2042143324 @default.
• W2101059527 cites W2042634005 @default.
• W2101059527 cites W2044113923 @default.
• W2101059527 cites W2044141660 @default.
• W2101059527 cites W2044587079 @default.
• W2101059527 cites W2046593868 @default.
• W2101059527 cites W2048837058 @default.
• W2101059527 cites W2049715091 @default.
• W2101059527 cites W2050029927 @default.
• W2101059527 cites W2052980876 @default.
• W2101059527 cites W2053203104 @default.
• W2101059527 cites W2053940212 @default.
• W2101059527 cites W2054762926 @default.
• W2101059527 cites W2057098163 @default.
• W2101059527 cites W2057400091 @default.
• W2101059527 cites W2058543554 @default.
• W2101059527 cites W2060049279 @default.
• W2101059527 cites W2060113694 @default.
• W2101059527 cites W2061672777 @default.
• W2101059527 cites W2064632813 @default.

• next